Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic heart signals could help ER doctors spot hidden heart risk

NCT ID NCT07822581

Diagnosis Sponsor: SB Technology, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are testing whether a non-invasive device that reads the heart's magnetic signals can help emergency department doctors tell high-risk from low-risk chest pain. The study enrolls adults 22 and older who arrive with symptoms suggesting a possible heart attack and who fall into a moderate-risk group based on a standard scoring tool. Participants receive a magnetocardiography scan alongside their usual care, and researchers use the collected signals and clinical data to train machine learning algorithms to detect high-risk coronary artery disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnetocardiography using the SandboxAQ CardiAQ System, a non-invasive device that measures the heart's magnetic signals
What this could lead to
If it works, emergency doctors could get a faster, non-invasive way to spot which chest pain patients face high risk of coronary artery disease, helping them decide who needs urgent care.
What could go wrong
This is a data-collection study to train computer algorithms, not a test of whether the approach improves patient outcomes. The magnetic signals may not reliably separate high-risk from low-risk patients, and the algorithms could fail to work in real emergency settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients in the ED presenting with symptoms suggestive of acute coronary syndromes, with a HEART Score of 4 or above, and after the first ECG and troponin results have been obtained to rule-out STEMI or obvious non-ACS are potential candidates for this study. This represents the "grey-zone", suspected non-ST-elevation acute coronary syndrome (NSTE-ACS) patient population that is time-consuming to triage and often creates a bottleneck in the ED.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women and men aged 22 years and older * Participant presenting with signs and symptoms suggestive of NSTE-ACS * In ED chest pain/NSTE-ACS care pathway * HEART Score 4+ * Have received their first troponin result and can accommodate an MCG scan before the second troponin result. Exclusion Criteria: * Unable to provide informed consent * ST elevation myocardial infarction (STEMI) * Active arrhythmia (as seen on the most recent ECG) such as atrial fibrillation, atrial flutter, ventricular tachycardia * Acute hemodynamic instability * Inability to lie supine and still for 5-10 minutes * Known or suspected pregnancy * Unable or unwilling to comply with required follow-up * Metallic passive implants that would make the participant unsuitable for MCG (e.g. spinal implants, metal shoulder replacements, dental implants.. etc.) * Active implantable medical devices (e.g. pacemakers, neurostimulators.. etc.) * Active illegal drug use per history of present illness * Contraindicated for temporary removal of telemetry during MCG scan * Clear non-ischemic cause for symptoms (e.g. trauma, viral infection, valve disease) * Clinical conditions that in the opinion of the Investigator would compromise the safety of the participant or ability to complete the protocol (e.g., exceeds bed weight limit, allergy to adhesives)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndromes (ACS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Chest Pain coronary artery disorder Non-ST Elevated Myocardial Infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndromes (ACS) Chest pain Coronary artery disease (CAD) Nste-acs (nstemi and ua)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • UCSF - Zuckerberg San Francisco General Hospital and Trauma Center

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.